Alfa Wassermann is a point of reference in the Contract Manufacturing sector being a leading company able to provide an integrated and exhaustive service covering all aspects of this activity, and to be a unique partner in outsourcing activities for the manufacturing of nearly all pharmaceutical forms, in the volumes required, for outside bodies. High qualitative standards and the utmost reliability are always ensured, thanks to the know-how obtained in many years’ experience, the use of innovative technologies and a modern plant, which has been recently enlarged and further developed.
James E. Gregory, UPM Pharmaceuticals||October 7, 2015 Pharmaceutical and biopharmaceutical companies large and small are increasingly relying on third-party providers for support at all stages of drug development. To realize efficiencies, they are at the same time reducing the number of suppliers to a preferred few with whom they can form strategic partnerships.
Franklin Spriggs, Stephanie Mowery and Bo Kowalcyk, AIT Bioscience ||October 7, 2015 ADCs are a breakthrough cancer treatment that can deliver cytotoxins directly to cancer cells without the sweeping collateral damage of traditional chemotherapy.
Suhasini Sharma, Sciformix Corporation ||September 11, 2015 Global biologics market will expand to $250 billion annually by 2020, with biosimilars and non-original biologics commanding 4-10% of that market